Effects of reconcile (fluoxetine) chewable tablets plus behavior management for canine separation anxiety.
Canine separation anxiety is a common behavioral problem presented to veterinarians. Associated behaviors are distressing to both dog and owner, have the potential to disrupt the human-companion animal bond, and may lead to euthanasia. The results of this study demonstrate the clinical efficacy and safety of Reconcile (fluoxetine, 1 to 2 mg/kg/day [0.45 to 0.91 mg/lb/day]), in conjunction with behavior management, for the treatment of canine separation anxiety. The beef flavored chewable formulation was palatable to treated dogs and easy to administer. This study provides to veterinarians and owners valuable information about an effective separation anxiety treatment plan that combines use of Reconcile with behavior modification.
Simpson
Barbara Sherman
BS
Veterinary Behavior Clinic, Southern Pines, NC 28387, USA.
Landsberg
Gary M
GM
Reisner
Ilana R
IR
Ciribassi
John J
JJ
Horwitz
Debra
D
Houpt
Katherine A
KA
Kroll
Tracy L
TL
Luescher
Andrew
A
Moffat
Kelly S
KS
Douglass
Genefer
G
Robertson-Plouch
Carol
C
Veenhuizen
Melissa F
MF
Zimmerman
Alan
A
Clark
Terrence P
TP
D000284:Administration, Oral; D000818:Animals; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage*; D001010:Anxiety, Separation / Q000188:drug therapy* / Q000523:psychology; D001522:Behavior, Animal; D002170:Canada; D004283:Dog Diseases / Q000188:drug therapy* / Q000523:psychology; D004285:Dogs; D004311:Double-Blind Method; D005473:Fluoxetine / Q000008:administration & dosage*; D001841:Human-Animal Bond; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage*; D016896:Treatment Outcome; D014481:United States
D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine; D017367:Selective Serotonin Reuptake Inhibitors